Skip to Main Content

Paper Details

Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
JACC Heart Fail
7
2023
ASCVD, Atherosclerotic Cardiovascular Disease, HF, Heart Failure, Patients, SGLT2, T2DM, Type 2 Diabetes, atherosclerotic cardiovascular disease, glucose, heart failure, hemoglobin A1c, ischemic heart, men, patients, sodium, sodium-glucose cotransporter-2, type 2 diabetes
Author NameAffiliation
David J RamseyMichael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations in Quality, Baylor College of Medicine
Michelle T LeeBaylor College of Medicine
Dhruv MahttaBaylor College of Medicine
Vijay NambiBaylor College of Medicine, Michael E. DeBakey Veterans Affairs Medical Center
Christie M BallantyneBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Laura A PetersenSection of Health Services Research, Baylor College of Medicine
Joseph G RogersTexas Heart Institute
Sankar D NavaneethanBaylor College of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, USA Institute of Clinical and Translational Research
Salim S ViraniThe Aga Khan University, Pakistan Michael E. DeBakey Veterans Affairs Medical Center, Texas Heart Institute, and Baylor College of Medicine
  • 1 - 10

Datasets

Release 1.2